Legend Biotech Corporation American Depositary Shares (LEGN)
Legend Biotech Corporation (LEGN) Q3 2024 Earnings Call Transcript
Legend Biotech Corporation (NASDAQ:LEGN ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Jessie Yeung - Vice President of Investor Relations and Finance Ying Huang - Chief Executive Officer Lori Macomber - Chief Financial Officer Mythili Koneru - Chief Medical Officer Steve Gavel - Senior Vice President, Commercial Development, U.S. & Europe Conference Call Participants Gena Wang - Barclays Kelly Shi - Jefferies Jessica Fye - JPMorgan Kostas Biliouris - BMO Capital James Shin - DB Vikram Purohit - Morgan Stanley Mitchell Kapoor - H.C. Wainright Rick Bienkowski - Cantor Fitzgerald Sean McCutcheon - Raymond James Operator Ladies and gentlemen, thank you for standing by.
Legend Biotech (LEGN) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Legend Biotech (LEGN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Legend Biotech (LEGN) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Legend Biotech (LEGN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Wall Street Analysts Believe Legend Biotech (LEGN) Could Rally 90.83%: Here's is How to Trade
The mean of analysts' price targets for Legend Biotech (LEGN) points to a 90.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Legend Biotech to set up new R&D facility in Philadelphia
Legend Biotech said on Thursday it would set up a new research and development facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies.
Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients
Friday, Legend Biotech Corporation LEGN and Johnson & Johnson JNJ announced late-breaking three-year follow-up data from the Phase 3 CARTITUDE-4 study.
Legend Biotech: Entering Accelerated Growth Phase, Carvykti Positions Company For Valuation Expansion
Carvykti, a CAR-T therapy co-developed by Legend Biotech & J&J, is central to second-line multiple myeloma treatment. Both firms are actively scaling up production across bases. Carvykti sales surged 60% YoY, reaching US$343 million in 1H2024, forecasting US$1 bilion+ for the full year. Rumors since July claim Legend Biotech faced a takeover bid, with fresh whispers of pricing disputes in negotiations this week.
Legend Biotech Corporation (LEGN) Q2 2024 Earnings Call Transcript
Legend Biotech Corporation (NASDAQ:LEGN ) Q2 2024 Earnings Call Transcript August 9, 2024 8:00 AM ET Company Participants Jessie Yeung - VP of IR & Finance Ying Huang - CEO Lori Macomber - CFO Steve Gavel - Head of Commercial Development for US and Europe Guowei Fang - CSO Conference Call Participants Gena Wang - Barclays Jessica Fye - JPMorgan Kelly Shi - Jefferies Ash Verma - UBS Leonid Timashev - RBC Capital Markets Jonathan Miller - Evercore ISI Yaron Werber - TD Cowen James Shin - Deutsche Bank Vikram Purohit - Morgan Stanley Justin Zelin - BTIG Mitchell Kapoor - H.C. Wainwright George Farmer - Scotiabank Rick Bienkowski - Cantor Fitzgerald Sean McCutcheon - Raymond James Asthika Goonewardene - Truist Operator Ladies and gentlemen, thank you for standing by.
Legend Biotech (LEGN) Up 12% on Reports of Takeover Bid
A third-party article suggests that Legend Biotech (LEGN) hired investment banking firm Centerview Partners to help its board review the takeover offer.
Legend Biotech (LEGN) Surges 12.1%: Is This an Indication of Further Gains?
Legend Biotech (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst
Shares of cell therapy company Legend Biotech Corp LEGN were trading lower on Monday, after being among the top pharma gainers in the first week of June.
